132 related articles for article (PubMed ID: 9616188)
1. In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists.
Hamelin BA; Bouayad A; Drolet B; Gravel A; Turgeon J
Drug Metab Dispos; 1998 Jun; 26(6):536-9. PubMed ID: 9616188
[TBL] [Abstract][Full Text] [Related]
2. Interaction of terfenadine and its primary metabolites with cytochrome P450 2D6.
Jones BC; Hyland R; Ackland M; Tyman CA; Smith DA
Drug Metab Dispos; 1998 Sep; 26(9):875-82. PubMed ID: 9733666
[TBL] [Abstract][Full Text] [Related]
3. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity.
Hamelin BA; Bouayad A; Méthot J; Jobin J; Desgagnés P; Poirier P; Allaire J; Dumesnil J; Turgeon J
Clin Pharmacol Ther; 2000 May; 67(5):466-77. PubMed ID: 10824625
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of H1-antihistamines on CYP2D6- and CYP2C9-mediated drug metabolic reactions in human liver microsomes.
He N; Zhang WQ; Shockley D; Edeki T
Eur J Clin Pharmacol; 2002 Feb; 57(12):847-51. PubMed ID: 11936702
[TBL] [Abstract][Full Text] [Related]
5. Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation.
Akutsu T; Kobayashi K; Sakurada K; Ikegaya H; Furihata T; Chiba K
Drug Metab Dispos; 2007 Jan; 35(1):72-8. PubMed ID: 17020955
[TBL] [Abstract][Full Text] [Related]
6. Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes.
Nakamura K; Yokoi T; Kodama T; Inoue K; Nagashima K; Shimada N; Shimizu T; Kamataki T
J Pharmacol Exp Ther; 1998 Feb; 284(2):437-42. PubMed ID: 9454781
[TBL] [Abstract][Full Text] [Related]
7. Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms.
Hiroi T; Ohishi N; Imaoka S; Yabusaki Y; Fukui H; Funae Y
J Pharmacol Exp Ther; 1995 Feb; 272(2):939-44. PubMed ID: 7853212
[TBL] [Abstract][Full Text] [Related]
8. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6.
Shin JG; Soukhova N; Flockhart DA
Drug Metab Dispos; 1999 Sep; 27(9):1078-84. PubMed ID: 10460810
[TBL] [Abstract][Full Text] [Related]
9. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine.
Abdel-Rahman SM; Marcucci K; Boge T; Gotschall RR; Kearns GL; Leeder JS
Drug Metab Dispos; 1999 Jul; 27(7):770-5. PubMed ID: 10383919
[TBL] [Abstract][Full Text] [Related]
10. The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy).
Van LM; Heydari A; Yang J; Hargreaves J; Rowland-Yeo K; Lennard MS; Tucker GT; Rostami-Hodjegan A
J Psychopharmacol; 2006 Nov; 20(6):834-41. PubMed ID: 16478752
[TBL] [Abstract][Full Text] [Related]
11. CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes.
Nakamura K; Yokoi T; Inoue K; Shimada N; Ohashi N; Kume T; Kamataki T
Pharmacogenetics; 1996 Oct; 6(5):449-57. PubMed ID: 8946477
[TBL] [Abstract][Full Text] [Related]
12. Mechanism-based inhibition of human liver microsomal cytochrome P450 2D6 (CYP2D6) by alkamides of Piper nigrum.
Subehan ; Usia T; Kadota S; Tezuka Y
Planta Med; 2006 May; 72(6):527-32. PubMed ID: 16808005
[TBL] [Abstract][Full Text] [Related]
13. Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles.
Bogni A; Monshouwer M; Moscone A; Hidestrand M; Ingelman-Sundberg M; Hartung T; Coecke S
Toxicol In Vitro; 2005 Aug; 19(5):621-9. PubMed ID: 15893449
[TBL] [Abstract][Full Text] [Related]
14. Antihistamines.
Armstrong SC; Cozza KL
Psychosomatics; 2003; 44(5):430-4. PubMed ID: 12954920
[TBL] [Abstract][Full Text] [Related]
15. Arylacetamide kappa opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity.
Le Bourdonnec B; Ajello CW; Seida PR; Susnow RG; Cassel JA; Belanger S; Stabley GJ; DeHaven RN; DeHaven-Hudkins DL; Dolle RE
Bioorg Med Chem Lett; 2005 May; 15(10):2647-52. PubMed ID: 15863335
[TBL] [Abstract][Full Text] [Related]
16. Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components.
Chatterjee P; Franklin MR
Drug Metab Dispos; 2003 Nov; 31(11):1391-7. PubMed ID: 14570772
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists.
Martínez C; Albet C; Agúndez JA; Herrero E; Carrillo JA; Márquez M; Benítez J; Ortiz JA
Clin Pharmacol Ther; 1999 Apr; 65(4):369-76. PubMed ID: 10223772
[TBL] [Abstract][Full Text] [Related]
18. Classic histamine H1 receptor antagonists: a critical review of their metabolic and pharmacokinetic fate from a bird's eye view.
Sharma A; Hamelin BA
Curr Drug Metab; 2003 Apr; 4(2):105-29. PubMed ID: 12678691
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine.
Obach RS; Pablo J; Mash DC
Drug Metab Dispos; 1998 Aug; 26(8):764-8. PubMed ID: 9698290
[TBL] [Abstract][Full Text] [Related]
20. Minimizing polymorphic metabolism in drug discovery: evaluation of the utility of in vitro methods for predicting pharmacokinetic consequences associated with CYP2D6 metabolism.
Gibbs JP; Hyland R; Youdim K
Drug Metab Dispos; 2006 Sep; 34(9):1516-22. PubMed ID: 16763018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
